Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

$140.1B

Market Cap • 4/3/2025

1987

(38 years)

Founded

1992

(33 years ago)

IPO

NASDAQ

Listing Exchange

Flag of US

Foster City

Headquarters • California

S&P500 Participant

Index Composite • 2025